1. Home
  2. MYGN vs NPCE Comparison

MYGN vs NPCE Comparison

Compare MYGN & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.00

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Logo Neuropace Inc.

NPCE

Neuropace Inc.

HOLD

Current Price

$15.48

Market Cap

432.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYGN
NPCE
Founded
1991
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
444.2M
432.3M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
MYGN
NPCE
Price
$5.00
$15.48
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$7.64
$18.33
AVG Volume (30 Days)
1.3M
165.9K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.03
EPS
N/A
N/A
Revenue
$771,400,000.00
$99,986,000.00
Revenue This Year
$6.89
$0.90
Revenue Next Year
$5.35
$24.46
P/E Ratio
N/A
N/A
Revenue Growth
2.33
25.13
52 Week Low
$3.76
$7.56
52 Week High
$8.59
$18.97

Technical Indicators

Market Signals
Indicator
MYGN
NPCE
Relative Strength Index (RSI) 56.21 62.07
Support Level $4.23 $15.25
Resistance Level $5.67 $15.71
Average True Range (ATR) 0.29 0.67
MACD 0.07 0.22
Stochastic Oscillator 70.69 91.26

Price Performance

Historical Comparison
MYGN
NPCE

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

About NPCE Neuropace Inc.

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Share on Social Networks: